MVZ fuer Haematologie und Onkologie Ravensburg GmbH — Clinical Trial Site

28 Registered trials

14 Currently recruiting

Organisation

MVZ fuer Haematologie und Onkologie Ravensburg GmbH

Location

Ravensburg, Germany

Identifier

ORG-100053203

Address

Elisabethenstrasse 19, 88212, Germany

Departments

-
#3115: Studienzentrum Onkologie Ravensburg
Fachärzte für Innere Medizin, Hämatologie und Onkologie
Haematology and Oncology
Hämatologie und Onkologie
Hämatologie, Onkologie
Hämatologie/Onkologie
Hematology and Oncology
MVZ fuer Haematologie und Onkologie Ravensburg GmbH - Studienzentrum
MVZ für Hämatologie und Onkologie Ravensburg GmbH – Studienzentrum
N/A
Oncology
Onkologie Hämatologie
Studienzentrum
Studienzentrum Onkologie Ravensburg
Women’s Clinic,Breast center, Gynecological Cancer Center

Clinical trials at this site (28)

Search interface

NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
A PROSPECTIVE, OPEN-LABEL, MULTICENTER, RANDOMIZED, PHASE 3 TRIAL OF ACALABRUTINIB, OBINUTUZUMAB AND VENETOCLAX (GAVE) COMPARED TO OBINUTUZU… Recruiting

2023-506414-46-00 High risk patients defined as having at least one of th 5 2022-04-22
ZANGEA – Phase II Study of Zanidatamab in Combination with Pembrolizumab and Chemotherapy in HER2 and PD-L1 Positive Metastatic Gastroesopha… Recruiting

2025-522718-22-00 Gastroesophageal Adenocarcinoma 4 2025-12-16
FUTURE Recruiting

2024-517573-24-00 Colorectal cancer 4 2025-12-08
A Study to Learn About the Study Medicine Called PF-07248144 in Combination with Fulvestrant in People with HR-positive, HER2-negative Advan… Recruiting

2025-520566-22-00 Hormone Receptor-Positive, HER2-Negative Advanced/Metas 5 2025-11-10
– IKF/AIO-QUINTIS – A Randomized Phase II Trial Evaluating Fruquintinib in Combination with Tislelizumab in Microsatellite Stable / Profici… Recruiting

2024-519929-38-00 Metastatic Colorectal Cancer without liver metastases 4 2025-10-27
A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (… Recruiting

2023-510294-34-00 small lymphocytic lymphoma (SLL) 5 2025-06-12
Pre-Operative Treatment in rEseCTable cOlon canceR (PROTECTOR/FIRE-10; AIO-KRK-0620; IAG-VO-0323) Prospective, randomized, open-label, multi… Recruiting

2023-508076-11-00 Colon cancer staged T3-4 and/or nodal positive by CT an 5 2025-04-01
Phase II study evaluating the addition of elacestrant, an oral selective estrogen receptor degrader (SERD), to standard-of-care olaparib in … Recruiting

2023-504925-38-00 patients with hormone receptor (HR)-positive, HER2-nega 4 2024-12-10
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
Phase II neoadjuvant study evaluating capivasertib plus fulvestrant vs fulvestrant in patients with primary high-risk lobular breast cancer-… Recruiting

2023-509292-17-00 primary high-risk lobular breast cancer 4 2024-11-08
MorningLyte: Evaluation of the benefits of the combination of mosunetuzumab plus lenalidomide versus a treatment with anti-CD20 monoclonal a… Recruiting

2023-505436-35-00 Untreated FLIPI 2-5 Follicular Lymphoma 5 2024-06-03
Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A ra… Recruiting

2023-504141-31-00 Metastatic HR positive, HER2 negative breast cancer 4 2024-01-17
MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer Recruiting

2024-511219-78-00 epithelial ovarian cancer 5 2023-02-28
A trial to learn more about the effects of ribociclib taken with endocrine therapy in patients with early breast cancer. Ended

2022-503001-38-01 HR-positive HER-2- negative Breast Cancer 5 2025-07-08
A Study of Camizestrant in ER+/HER2- Early Breast Cancer After at Least 2 Years of Standard Adjuvant Endocrine-Based Therapy Ended

2022-501024-20-00 ER+/HER2- Early Breast Cancer 5 2023-07-25
A clinical trial to compare the effectiveness and safety of giredestrant with a subcutaneous combination of pertuzumab and trastuzumab versu… Ended

2022-500014-26-00 Locally-Advanced unresectable or Metastatic breast canc 5 2022-06-24
A Study of Relatlimab plus Nivolumab in Combination with Chemotherapy vs. Nivolumab in Combination with Chemotherapy in Participants with St… Ended

2023-508372-10-00 Non small Cell Lung cancer 4 2021-05-19
Clinical trial comparing Trastuzumab Deruxtecan with Trastuzumab Emtansine in high-risk HER2-positive patients with residual breast cancer f… Ended

2023-507961-24-00 High-Risk HER2-Positive Breast Cancer 5 2021-04-19
A phase 3 multicentre, randomized, prospective, open-label trial of Ibrutinib monotherapy versus fixed-duration Venetoclax plus Obinutuzumab… Ended

2022-500439-35-00 treatment-naive chronic lymphocytic leukemia 5 2021-02-11
A randomized, controlled, open-label, phase III-trial on Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing abemaciclib combi… Ended

2023-509242-35-00 HR+/HER2- early breast cancer 5 2020-07-23
A study to determine whether the addition of Dostarlimab (TSR-042) delays recurrence of advanced endometrial cancer Ended

2023-506551-23-00 Recurrent or primary advanced (Stage III or IV) endomet 5 2019-11-21
A phase III multi-center, randomized, open-label trial to evaluate efficacy and safety of ribociclib with endocrine therapy as adjuvant trea… Ended

2023-510357-42-00 hormone receptor (HR)-positive, HER2-negative, early br 5 2019-05-22
The FIRST (First-line ovarian cancer treatment with Niraparib plus TSR-042) Study Ended

2024-510605-28-00 Stage 3 or 4 Non-mucinous Epithelial Ovarian Cancer 5 2018-11-27